A multicenter, phase III, open-label (EXPEDITION-3) study was conducted to explore the safety and efficacy of glecaprevir/pibrentasvir therapy in treatment-naïve Brazilian adults having hepatitis C infection genotype 1-6.
In treatment-naive adults suffering from hepatitis C infection with compensated liver cirrhosis (F4) or without liver cirrhosis (F2 or F3), glecaprevir/pibrentasvir was found to be well-tolerated and demonstrated high efficacy.
A multicenter, phase
III, open-label (EXPEDITION-3) study was conducted to explore the safety and
efficacy of glecaprevir/pibrentasvir therapy in treatment-naïve Brazilian
adults having hepatitis C infection genotype 1-6.
Participants without cirrhosis and with compensated cirrhosis were recruited in this study and were administered eight or 12 weeks of glecaprevir/pibrentasvir therapy respectively. Among the 100 patients enrolled, 75 received 8 weeks’ treatment, and 25 received 12 weeks’ treatment.
The rate of sustained virologic response after treatment was the primary outcome parameter and the on-treatment virologic failure and decline rates were the secondary outcome parameters. The baseline polymorphisms were precisely evaluated in nonstructural viral protein 5A (NS5A) and nonstructural viral protein 3 (NS3). Lab abnormalities and noxious events were also examined.
The sustained virologic response at week 12 after the treatment was high (98/100 [98%]), as shown below:
Data
are n (%) unless stated otherwise. †2-sided 95% CI based on the
Wilson score method. CI, confidence interval; ITT, intention-to-treat; mITT,
modified ITT; N/A, not applicable; OTVF, ontreatment virologic failure; SVR12,
sustained virologic response at post-treatment Week 12
It remained elevated despite host factors and baseline viral factors including hepatitis C virus RNA levels, demographics, polymorphisms in NS3 and/or NS5A, genotype, and comorbidities.
Only
55% of patients were found to report ≥1 adverse event (the most common being
headache [18%]). No serious adverse effect was found to be related to the drug.
There were no hepatic decompensations reported.
Glecaprevir/pibrentasvir
is a well-tolerated and efficient therapy in treatment-naïve Brazilian patients
who are suffering from hepatitis C infection with compensated cirrhosis and
without cirrhosis.
Annals of Hepatology
Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults with Chronic Hepatitis C Virus Genotypes 1-6 in Brazil
Mario Peribañez-Gonzalez et al.
Comments (0)